#2 - Intellia Therapeutics (NASDAQ:NTLA)
It's appropriate to include Intellia Therapeutics Inc. (NASDAQ: NTLA) on a list of gene editing stocks. And it’s also important to include them immediately after CRISPR Therapeutics. Intellia uses CRISPR-Cas9 technology for its in vivo gene editing pipeline that is attempting to treat more conditions.
For example, the company’s lead candidate, NTLA-2001 is being developed as a potential treatment for Transthyretin Amyloidosis (ATTR). The company has reported clinical data supportive of its technology, but approval is still years away.
The good news for investors is that Intellia has partnered with Regeneron Pharmaceuticals inc. (NASDAQ: REGN) to bring NTLA-2001 to market. And there is some belief that NTLA-2001 may eventually be approved as a treatment for other genetic diseases such as Alzheimer’s Disease, Parkinson’s, and Huntington’s Disease.
The Intellia analyst forecast on MarketBeat gives NTLA stock a Moderate Buy rating with a $67.25 price target. That’s 215% above the stock’s closing price on August 7, 2024. And for those who place a value on such things, Cathie Wood’s ARK Invest fund increased its stake in the stock to 5.5% in the second quarter of 2024.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Read More - Current Price
- $14.79
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 12 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $54.94 (271.5% Upside)
